Karan Bajaj, who revolutionized the coding domain for school-going students through his edtech unicorn, WhiteHat Jr., is again in the news with a massive $16M venture fund raised for his new startup, Complement1.
The seed capital funding round was led by global edtech investor Owl Ventures and also backed by India-based Blume Ventures, alongside participation from 8VC, B Capital, and various angel investors.
Primarily launched in stealth mode but now operating publicly, Complement1 envisions transforming the scattered experience faced by cancer patients by integrating diagnostics, treatment pathways, and regular care through technology and clinical expertise.
Speaking about his startup’s plans, Karan said, “Cancer care is extremely fragmented. Patients often find themselves confused and unsupported during a very vulnerable time. We want to change that with an end-to-end platform that combines world-class clinical care, research, and technology.”
Bajaj made headlines during COVID when WhiteHat Jr. was acquired by another edtech giant, BYJU’S, for a whopping $300M. Now, through his new startup, he plans to pivot to healthcare and offer cancer patients a one-stop diagnostic ecosystem from detection to recovery.
He expects his startup to go live with initial services during early 2025, with an aim toward international expansion subsequently.
With this fresh funding crop, Karan plans to develop Complement1’s product, onboard medical experts, and even kickstart launch programs in chosen Indian cities.
“Owl Ventures has backed Karan before, and we’re excited to support him again in a completely new domain. The problem he’s solving is massive, and it requires the kind of structured thinking he brings to the table,” said Amit Patel, Managing Director at Owl Ventures.
India continues to face a sharp rise in cancer cases, yet most of the population lacks access to structured and affordable care. With Complement 1, Bajaj hopes to plug that gap by fusing empathy with innovation in a domain where both are often lacking.
As deeptech and healthtech continue to gain momentum in India, Complement 1’s entry marks a significant push toward rethinking care delivery, not just for cancer, but as a model for broader healthcare innovation in the country.